Skip to main content
Log in

Leukocytosis is linked to thrombosis at diagnosis, while JAK2 V617F mutation is associated with thrombosis during the course of essential thrombocythemia

  • Letter to the Editor
  • Published:
International Journal of Hematology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Campbell PJ, Scott LM, Buck G, et al. Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet. 2005;366:1945–53.

    Article  CAS  PubMed  Google Scholar 

  2. James C, Ugo V, Le Couédic J-P, Staerk J, Delhoummeau F, Flacount C, et al. A unique clonal JAK2 mutation leading to constitutive signaling causes polycythemia vera. Nature. 2005;434:1144–8.

    Article  CAS  PubMed  Google Scholar 

  3. Ohyashiki K, Aota Y, Akahane D, Gotoh A, Ohyashiki JH. JAK2V617F mutational status as determined by semiquantitative sequence-specific primer-single molecule fluorescence detection assay is linked to clinical features in chronic myeloproliferative disorders. Leukemia. 2007;21:1097–9.

    Article  CAS  PubMed  Google Scholar 

  4. Ohyashiki K, Ito Y, Hori K, Sato K, Makino T, Ohyashiki JH. Thrombosis can occur at any phase of essential thrombocythemia with JAK2V617F mutation: a single institutional study in Japan. Leukemia. 2007;21:1570–1.

    Article  CAS  PubMed  Google Scholar 

  5. Finazzi G, Rambaldi A, Guerini V, Carobbio A, Barbui T. Risk of thrombosis in patients with essential thrombocythemia and polycythemia vera according to JAK2 V617F mutation status. Haematologica. 2007;92:135–6.

    Article  PubMed  Google Scholar 

  6. Carobbio A, Finazzi G, Guerini V, et al. Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors and Jak2 mutation status. Blood. 2007;105:2310–3.

    Article  Google Scholar 

  7. Scott LM, Tong W, Levine RL, et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med. 2007;356:459–68.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Tefferi A, Thiele J, Orazi A, et al. Proposals amd rationale for revison of the World Heal Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: Recommendations from an ad hoc international expert panel. Blood. 2007;110:1092–7.

    Article  CAS  PubMed  Google Scholar 

  9. Michiels JJ, De Raeve H, Hebeda K, et al. WHO bone marrow features and European clinical, molecular, and pathological (ECMP) criteria for the diagnosis of myeloprolierative disorders. Leuk Res. 2007;31:1031–8.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

Thanks are due to Professor J Patrick Barron of the International Medical Communications Center of Tokyo Medical University for his review of this manuscript. This work was supported in part by the “High-Tech Research Center” Project from the Ministry of Education, Culture, Sports and Technology (MEXT) and by the “University-Industry Joint Research Project” from MEXT. This work has been also supported by Foundation for Promotion of Cancer Research in Japan (JHO).

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Kazuma Ohyashiki.

About this article

Cite this article

Ohyashiki, K., Kiguchi, T., Ito, Y. et al. Leukocytosis is linked to thrombosis at diagnosis, while JAK2 V617F mutation is associated with thrombosis during the course of essential thrombocythemia. Int J Hematol 87, 446–448 (2008). https://doi.org/10.1007/s12185-008-0080-9

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12185-008-0080-9

Keywords

Navigation